Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


06.11.2017

3 Blood
7 Br J Haematol
2 Cancer
4 Cancer Res
3 Haematologica
1 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
1 J Immunol
4 Leuk Lymphoma
4 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Blood

  1. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available

  2. FISH K, Sora RP, Schaller SJ, Longnecker R, et al
    EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.
    Blood. 2017 Oct 26. pii: blood-2017-07-796821. doi: 10.1182/blood-2017-07-796821
    PubMed     Text format     Abstract available

  3. BARTLETT NL, Costello BA, LaPlant BR, Ansell SM, et al
    Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial.
    Blood. 2017 Oct 26. pii: blood-2017-09-804641. doi: 10.1182/blood-2017-09-804641
    PubMed     Text format     Abstract available


    Br J Haematol

  4. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Text format     Abstract available

  5. PFREUNDSCHUH M, Murawski N, Zeynalova S, Ziepert M, et al
    Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
    Br J Haematol. 2017;179:410-420.
    PubMed     Text format     Abstract available

  6. MANSO R, Sanchez-Beato M, Gonzalez-Rincon J, Gomez S, et al
    Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14984.
    PubMed     Text format    

  7. CHASE ML, Armand P
    Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14996.
    PubMed     Text format     Abstract available

  8. QIU Y, Li Z, Pouzoulet F, Vishnu P, et al
    Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.15009.
    PubMed     Text format    

  9. PRETTYJOHNS M, Hoskin P, McNamara C, Linch D, et al
    The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14990.
    PubMed     Text format     Abstract available

  10. GIULINO-ROTH L, O'Donohue T, Chen Z, Bartlett NL, et al
    Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Br J Haematol. 2017 Oct 29. doi: 10.1111/bjh.14951.
    PubMed     Text format     Abstract available


    Cancer

  11. AMMANN EM, Drake MT, Haraldsson B, Wallace RB, et al
    Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation.
    Cancer. 2017;123:4168-4177.
    PubMed     Text format     Abstract available

  12. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Text format     Abstract available


    Cancer Res

  13. HERRMANN A, Lahtz C, Nagao T, Song JY, et al
    CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.
    Cancer Res. 2017;77:5118-5128.
    PubMed     Text format     Abstract available

  14. TANG YC, Yuwen H, Wang K, Bruno PM, et al
    Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.
    Cancer Res. 2017;77:5272-5286.
    PubMed     Text format     Abstract available

  15. SPEHALSKI E, Capper KM, Smith CJ, Morgan MJ, et al
    MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress.
    Cancer Res. 2017;77:5327-5338.
    PubMed     Text format     Abstract available

  16. LI P, Wuthrick E, Rappaport JA, Kraft C, et al
    GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
    Cancer Res. 2017;77:5095-5106.
    PubMed     Text format     Abstract available


    Haematologica

  17. RUDELIUS M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, et al
    Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Haematologica. 2017 Oct 27. pii: haematol.2017.177162.
    PubMed     Text format     Abstract available

  18. NG SB, Chung TH, Kato S, Nakamura S, et al
    EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes.
    Haematologica. 2017 Nov 2. pii: haematol.2017.180430.
    PubMed     Text format     Abstract available

  19. BOSCH M, Akhter A, Chen BE, Mansoor A, et al
    A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
    Haematologica. 2017 Nov 2. pii: haematol.2017.179309.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  20. ARISTOPHANOUS M, Chi PM, Kao J, Williamson R, et al
    Deep-Inspiration Breath-Hold Intensity Modulated Radiation Therapy to the Mediastinum for Lymphoma Patients: Setup Uncertainties and Margins.
    Int J Radiat Oncol Biol Phys. 2017 Sep 25. pii: S0360-3016(17)33936.
    PubMed     Text format     Abstract available


    J Clin Oncol

  21. LUMINARI S, Ferrari A, Manni M, Dondi A, et al
    Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    J Clin Oncol. 2017 Nov 2:JCO2017741652. doi: 10.1200/JCO.2017.74.1652.
    PubMed     Text format     Abstract available

  22. MAURER MJ, Ellin F, Srour L, Jerkeman M, et al
    International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2017 Oct 26:JCO2017738195. doi: 10.1200/JCO.2017.73.8195.
    PubMed     Text format     Abstract available


    J Immunol

  23. CATALAN-DIBENE J, Vazquez MI, Luu VP, Nuccio SP, et al
    Identification of IL-40, a Novel B Cell-Associated Cytokine.
    J Immunol. 2017;199:3326-3335.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  24. CHEN Q, Staton AD, Ayer T, Goldstein DA, et al
    Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Oct 25:1-10. doi: 10.1080/10428194.2017.1390230.
    PubMed     Text format     Abstract available

  25. BELTRAN BE, Quinones P, Sanchez G, Paredes A, et al
    Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
    Leuk Lymphoma. 2017 Oct 30:1-3. doi: 10.1080/10428194.2017.1393666.
    PubMed     Text format    

  26. ITOH K, Igarashi T, Irisawa H, Aotsuka N, et al
    Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
    Leuk Lymphoma. 2017 Oct 30:1-8. doi: 10.1080/10428194.2017.1390233.
    PubMed     Text format     Abstract available

  27. GREIL C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, et al
    Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673.
    PubMed     Text format    


    PLoS One

  28. PEDERSEN MO, Gang AO, Brown P, Pedersen M, et al
    Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    PLoS One. 2017;12:e0186983.
    PubMed     Text format     Abstract available

  29. JORDI M, Marty J, Mordasini V, Lunemann A, et al
    IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus BZLF1 transcription in Akata Burkitt's lymphoma cells.
    PLoS One. 2017;12:e0186614.
    PubMed     Text format     Abstract available

  30. CINGOLANI A, Cozzi Lepri A, Teofili L, Galli L, et al
    Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population.
    PLoS One. 2017;12:e0186549.
    PubMed     Text format     Abstract available

  31. LIN GHY, Chai V, Lee V, Dodge K, et al
    TTI-621 (SIRPalphaFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
    PLoS One. 2017;12:e0187262.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  32. DUCKER GS, Ghergurovich JM, Mainolfi N, Suri V, et al
    Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma.
    Proc Natl Acad Sci U S A. 2017;114:11404-11409.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: